ID: h-24f6280d
Hypothesis
Apolipoprotein E4-Mediated Metabolic Dysfunction Correction via Liver X Receptor Agonism
Apolipoprotein E4-Mediated Metabolic Dysfunction Correction via Liver X Receptor Agonism.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 4 support✗ 4 oppose
🧪 Overview
Apolipoprotein E4-Mediated Metabolic Dysfunction Correction via Liver X Receptor Agonism
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["LXR-beta/NR1H2<br/>Nuclear Receptor"]
B["Oxysterol Ligand Binding<br/>24S-HC, 27-HC, GW3965"]
C["LXR/RXR Heterodimer<br/>DR4 Response Element"]
D["ABCA1/ABCG1<br/>Transcriptional Activation"]
E["APOE Lipidation<br/>Cholesterol Efflux"]
F["APOE4 Astrocytes<br/>LXR-beta Activity Reduced"]
G["Selective LXR-beta Agonist<br/>Avoids LIPID Toxicity"]
H["Cholesterol Homeostasis<br/>Neuroprotection"]
A --> B
B --> C
C --> D
D --> E
E --> H
F -.->|"impairs"| D
G --> C
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#1b5e20,stroke:#81c784,color:#81c784
style H fill:#1b5e20,stroke:#81c784,color:#81c784⚖️ Evidence
⚖️ Evidence Matrix4 supports4 contradicts
Supports
ApoE4 knock-in mice exhibit accumulation of neutral lipids and cholesterol esters in astrocytes, with impaired lipid efflux
Supports
LXR agonist (GW3965) treatment in ApoE4-targeted replacement mice reduces amyloid deposition and improves cognitive performance
Supports
Metabolomic profiling reveals distinct lipidomic signatures in ApoE4 vs. ApoE3 carriers, including elevated saturated free fatty acids
Supports
ABCA1 expression is reduced in ApoE4 astrocytes, limiting cholesterol efflux to ApoE particles
Contradicts
LXR agonists induce lipogenesis - GW3965 increases SREBP1c expression, leading to hepatic steatosis
Contradicts
All advanced LXR agonist programs terminated - Novartis LXR-623 Phase I failed (2010), VTP-45543 and others discontinued
Contradicts
ApoE4 carriers may not have dysfunction but different function - lipid droplet accumulation may be compensatory
Contradicts
LXR agonists have failed in metabolic syndrome trials, limiting translational potential
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — NR1H2
No curated PDB or AlphaFold mapping for NR1H2 yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for NR1H2 (LXRβ), APOE from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for NR1H2 (LXRβ), APOE.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.9%
Volatility
Low
0.0110
Events (7d)
3
Price History
▲21.0%💾 Resource Usage
LLM Tokens
38,010
$0.1140
Total Cost
$0.1140
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF male E4-targeted replacement (E4-TR) mice on 60% high-fat diet receive LXRβ agonist T0901317 at 30 mg/kg/day via oral gavage for 16 weeks starting at 8 weeks of age, THEN hepatic triglyceride conte | Hepatic triglyceride content reduction ≥40%; serum β-hydroxybutyrate increase ≥50%; hepatic steatosis score reduction from NASH/NAFLD to normal or mild (score ≤ | — no observation — | pending | 0.60 |
| IF cognitively unimpaired APOE4 homozygous adults aged 50-70 with metabolic syndrome (HOMA-IR >2.5) receive oral LXRβ agonist GW3965 at 10 mg/kg/day for 12 weeks, THEN plasma ApoE4 concentrations will | Plasma ApoE4 concentration decrease ≥25%; HOMA-IR reduction ≥30%; fasting glucose decrease ≥15 mg/dL; LDL-C reduction ≥20 mg/dL | — no observation — | pending | 0.55 |
🔮 Falsifiable Predictions (2)
pendingconf 60%
IF male E4-targeted replacement (E4-TR) mice on 60% high-fat diet receive LXRβ agonist T0901317 at 30 mg/kg/day via oral gavage for 16 weeks starting at 8 weeks of age, THEN hepatic triglyceride content will decrease by ≥40% and serum ketone levels will increase by ≥50% compared to vehicle-treated E
Predicted outcome: Hepatic triglyceride content reduction ≥40%; serum β-hydroxybutyrate increase ≥50%; hepatic steatosis score reduction from NASH/NAFLD to normal or mil
Falsification: No reduction in hepatic triglycerides or ketogenesis markers; hepatic triglyceride content remains >90% of vehicle control levels; or LXRβ agonist fails to cross blood-brain barrier and does not affec
pendingconf 55%
IF cognitively unimpaired APOE4 homozygous adults aged 50-70 with metabolic syndrome (HOMA-IR >2.5) receive oral LXRβ agonist GW3965 at 10 mg/kg/day for 12 weeks, THEN plasma ApoE4 concentrations will decrease by ≥25% and HOMA-IR will improve (decrease) by ≥30% compared to vehicle-treated APOE4 carr
Predicted outcome: Plasma ApoE4 concentration decrease ≥25%; HOMA-IR reduction ≥30%; fasting glucose decrease ≥15 mg/dL; LDL-C reduction ≥20 mg/dL
Falsification: No statistically significant change (p>0.05) in HOMA-IR or plasma ApoE4 levels between treatment and placebo groups; or ApoE4 levels increase rather than decrease with treatment
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.